search
Back to results

The INFUSE - Anterior Myocardial Infarction (AMI) Study

Primary Purpose

Acute Anterior Myocardial Infarction

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Abciximab local infusion
No local infusion
Thrombus aspiration
Sponsored by
Atrium Medical Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Anterior Myocardial Infarction

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • The subject must be >18 years of age;
  • Subject is experiencing clinical symptoms consistent with AMI (e.g., chest pain, arm pain, etc.,) >30 minutes duration and unresponsive to nitroglycerin;
  • Anterior MI with ECG showing at least 1 mm of ST-segment elevation in 2 or more contiguous leads in V1-V4, or new (or presumably new) left bundle branch block;
  • Anticipated symptom onset to balloon or aspiration time of ≤5 hours;
  • The subject and his/her physician are willing to comply with specified follow-up evaluations;
  • The subject or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided and signed written informed consent, approved by the appropriate Medical Ethics Committee (MEC) or Institutional Review Board (IRB)
  • Infarct artery located in the proximal or mid left anterior descending coronary artery, with TIMI 0/1/2 flow at the time of initial diagnostic angiography (prior to wire passage);
  • Based on coronary anatomy, PCI is indicated for revascularization;
  • Only one epicardial coronary artery will be treated;
  • Expected ability to deliver a ClearWay™ RX Infusion Catheter to the infarct lesion (absence of excessive tortuosity, diffuse disease or moderate/heavy calcification).

Key Exclusion Criteria:

  • Prior myocardial infarction, or known prior systolic dysfunction (known ejection fraction <40% by any prior measure or regional wall motion abnormalities);
  • An elective surgical procedure is planned that would necessitate interruption of anti-platelet agents during the first twelve months post enrollment;
  • Subjects who previously underwent coronary stent implantation and in whom coronary angiography demonstrates stent thrombosis to be the cause of the AMI;
  • Subject has previously undergone an angioplasty or stenting procedure in the left anterior descending artery;
  • Definite planned use of aspiration, atherectomy, thrombectomy and/or distal protection catheters prior to PTCA or stent implantation (other than in subjects randomized to thrombus aspiration);
  • Any contraindication to undergo MRI imaging.
  • Multivessel intervention required during the index procedure (subjects may be enrolled if treatment of more than one lesion in the LAD or its branches is required, however) (planned staged procedures are permitted with strong recommendation to be performed after 30-day clinical and MRI endpoints are completed);
  • Severe vessel tortuosity, diffuse disease or severe calcification is present which may impede successful delivery of the ClearWay™ RX Infusion Catheter or the Export® Aspiration Catheter;
  • Features are present highly unfavorable for PCI;
  • Target lesion is present within a bypass graft conduit;
  • MI is due to thrombosis within or adjacent to a previously implanted stent;
  • Left ventriculography demonstrates severe mitral regurgitation or a VSD;
  • Unprotected left main stenosis >40% or that will require intervention

Sites / Locations

  • Washington Adventist Hospital
  • Carolinas Medical Center-SHVI
  • Moses Cone Vascular Center
  • Geisinger Medical Center
  • Harrisburg Hospital/ Pinnacle Health
  • Wellmont Holston Valley Medical Center
  • Sentara Virginia Beach General Hospital
  • Landeskrankenhaus Braunau/Simbach
  • Landeskrankenhaus Bruck/Mur
  • Landeskrankenhaus Graz West
  • Univ. Klinik für Innere Medizin III Innsbruck
  • Univ. Klinik für Innere Medizin II
  • Charite- University Medicine Campus Benjamin Franklin
  • Klinikum Villingen Kardiologie
  • Facharzt fur Innere Medizin/Kardiologie
  • Universitätsmedizin Mannheim - I. Medizinische Klinik
  • Klinikum der Universität Regensburg
  • Universtitätsklinikuim Ulm
  • Ziekenhuis Rijnstate
  • Catharina Hospital Eindhoven
  • Isala Klinieken, Locatie de Weezenlanden
  • Polsko - Amerykańskie Kliniki Serca II Oddział Kardiologiczny American Heart of Poland Sp. z o.o.
  • Krakowskie Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii
  • Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie, Centrum Interwencyjne Leczenia Chorób Serca i Naczyń
  • SPZOZ Szpital Uniwersytecki w Krakowie, Samodzielna Pracownia Hemodynamiki i Angiografii
  • Pracownia Hemodynamiki Oddziału Kardiologicznego Wojewódzkiego Centrum Medycyny w Opolu
  • Centrum Kardiologii Inwazyjnej GVM Carint
  • Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie Pracownia Hemodynamiki I Katedry i Kliniki Kardiologii
  • Instytut Kardiologii im. Prymasa Tysiąclecia Kardynała Stefana Wyszyńskiego,I Samodzielna Pracownia Hemodynamiki
  • University Hospitals of Leicester - Glenfield Hospital
  • King's College Hospital
  • Manchester Royal Infirmary
  • Wythenshawe Hospital
  • Southampton University Hospital
  • Royal Victoria Hospital, Belfast Trust
  • Bristol Heart Institute
  • Golden Jubilee National Hospital
  • Freeman Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Local infusion, thrombus aspiration

Local infusion, no aspiration

No local infusion, thrombus aspiration

No local infusion, no aspiration

Arm Description

Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.

Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration

No local infusion of abciximab, thrombus aspiration.

No local infusion abciximab and no thrombus aspiration

Outcomes

Primary Outcome Measures

Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion
The primary endpoint of the INFUSE AMI study is infarct size as a percentage of total left ventricular mass at 30 days as measured by cardiac MRI (cMRI), comparing the pooled randomized active (abciximab) infusion to the pooled non infusion arms, without regard to aspiration.

Secondary Outcome Measures

Major Secondary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Aspiration vs. No Aspiration
The major secondary endpoint of the INFUSE AMI Study is infarct size as a percentage of total myocardial mass at 30 days measured by cardiac MRI (cMRI), comparing the pooled randomized aspiration arms to the pooled no aspiration arms, without regard to abciximab infusion.

Full Information

First Posted
September 11, 2009
Last Updated
May 31, 2013
Sponsor
Atrium Medical Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT00976521
Brief Title
The INFUSE - Anterior Myocardial Infarction (AMI) Study
Official Title
A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction
Study Type
Interventional

2. Study Status

Record Verification Date
May 2013
Overall Recruitment Status
Completed
Study Start Date
September 2009 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Atrium Medical Corporation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites. Subjects who present with anterior ST-elevation myocardial infarction (STEMI) and an occluded proximal or mid left anterior descending (LAD) with TIMI 0/1/2 flow will be eligible for randomization to one of the following arms: Local infusion of abciximab following thrombus aspiration Local infusion of abciximab and no thrombus aspiration No local infusion and thrombus aspiration No local infusion and no thrombus aspiration In addition, a cardiac magnetic resonance imaging (MRI) sub-study evaluating microvascular obstruction (MVO) will be performed with up to 160 subjects at up to 20 sites.
Detailed Description
The primary objective of the study is to demonstrate that among subjects undergoing primary PCI for anterior STEMI treated with a bivalirudin monotherapy anticoagulation strategy, the intracoronary infusion of an abciximab bolus with or without thrombus aspiration prior to stent implantation, compared to no infusion with or without thrombus aspiration (standard of care), results in 1) reduced infarct size measured by cardiac MRI at 30 days (range -7 days/+14 days; i.e., between 23 and 44 days), 2) reduce microvascular obstruction (MVO) by cardiac MRI at 5 + 2 days (i.e., between 3 and 7 days), 3) enhanced ST-segment resolution, 4) improved myocardial perfusion, 5) reduced thrombus burden and angiographic complications, and 6) no increase in major and minor bleeding.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Anterior Myocardial Infarction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
Participant
Allocation
Randomized
Enrollment
452 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Local infusion, thrombus aspiration
Arm Type
Experimental
Arm Description
Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.
Arm Title
Local infusion, no aspiration
Arm Type
Experimental
Arm Description
Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration
Arm Title
No local infusion, thrombus aspiration
Arm Type
Active Comparator
Arm Description
No local infusion of abciximab, thrombus aspiration.
Arm Title
No local infusion, no aspiration
Arm Type
Active Comparator
Arm Description
No local infusion abciximab and no thrombus aspiration
Intervention Type
Drug
Intervention Name(s)
Abciximab local infusion
Intervention Description
Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
Intervention Type
Other
Intervention Name(s)
No local infusion
Intervention Description
Intervention without local infusion
Intervention Type
Procedure
Intervention Name(s)
Thrombus aspiration
Intervention Description
Thrombus aspiration
Primary Outcome Measure Information:
Title
Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion
Description
The primary endpoint of the INFUSE AMI study is infarct size as a percentage of total left ventricular mass at 30 days as measured by cardiac MRI (cMRI), comparing the pooled randomized active (abciximab) infusion to the pooled non infusion arms, without regard to aspiration.
Time Frame
30 Days Post Index Procedure
Secondary Outcome Measure Information:
Title
Major Secondary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Aspiration vs. No Aspiration
Description
The major secondary endpoint of the INFUSE AMI Study is infarct size as a percentage of total myocardial mass at 30 days measured by cardiac MRI (cMRI), comparing the pooled randomized aspiration arms to the pooled no aspiration arms, without regard to abciximab infusion.
Time Frame
30 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: The subject must be >18 years of age; Subject is experiencing clinical symptoms consistent with AMI (e.g., chest pain, arm pain, etc.,) >30 minutes duration and unresponsive to nitroglycerin; Anterior MI with ECG showing at least 1 mm of ST-segment elevation in 2 or more contiguous leads in V1-V4, or new (or presumably new) left bundle branch block; Anticipated symptom onset to balloon or aspiration time of ≤5 hours; The subject and his/her physician are willing to comply with specified follow-up evaluations; The subject or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided and signed written informed consent, approved by the appropriate Medical Ethics Committee (MEC) or Institutional Review Board (IRB) Infarct artery located in the proximal or mid left anterior descending coronary artery, with TIMI 0/1/2 flow at the time of initial diagnostic angiography (prior to wire passage); Based on coronary anatomy, PCI is indicated for revascularization; Only one epicardial coronary artery will be treated; Expected ability to deliver a ClearWay™ RX Infusion Catheter to the infarct lesion (absence of excessive tortuosity, diffuse disease or moderate/heavy calcification). Key Exclusion Criteria: Prior myocardial infarction, or known prior systolic dysfunction (known ejection fraction <40% by any prior measure or regional wall motion abnormalities); An elective surgical procedure is planned that would necessitate interruption of anti-platelet agents during the first twelve months post enrollment; Subjects who previously underwent coronary stent implantation and in whom coronary angiography demonstrates stent thrombosis to be the cause of the AMI; Subject has previously undergone an angioplasty or stenting procedure in the left anterior descending artery; Definite planned use of aspiration, atherectomy, thrombectomy and/or distal protection catheters prior to PTCA or stent implantation (other than in subjects randomized to thrombus aspiration); Any contraindication to undergo MRI imaging. Multivessel intervention required during the index procedure (subjects may be enrolled if treatment of more than one lesion in the LAD or its branches is required, however) (planned staged procedures are permitted with strong recommendation to be performed after 30-day clinical and MRI endpoints are completed); Severe vessel tortuosity, diffuse disease or severe calcification is present which may impede successful delivery of the ClearWay™ RX Infusion Catheter or the Export® Aspiration Catheter; Features are present highly unfavorable for PCI; Target lesion is present within a bypass graft conduit; MI is due to thrombosis within or adjacent to a previously implanted stent; Left ventriculography demonstrates severe mitral regurgitation or a VSD; Unprotected left main stenosis >40% or that will require intervention
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Greg W Stone, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington Adventist Hospital
City
Takoma Park
State/Province
Maryland
ZIP/Postal Code
20912
Country
United States
Facility Name
Carolinas Medical Center-SHVI
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28203
Country
United States
Facility Name
Moses Cone Vascular Center
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27401
Country
United States
Facility Name
Geisinger Medical Center
City
Danville
State/Province
Pennsylvania
ZIP/Postal Code
17822
Country
United States
Facility Name
Harrisburg Hospital/ Pinnacle Health
City
Harrisburg
State/Province
Pennsylvania
ZIP/Postal Code
17110
Country
United States
Facility Name
Wellmont Holston Valley Medical Center
City
Kingsport
State/Province
Tennessee
ZIP/Postal Code
37660
Country
United States
Facility Name
Sentara Virginia Beach General Hospital
City
Virginia Beach
State/Province
Virginia
ZIP/Postal Code
23454
Country
United States
Facility Name
Landeskrankenhaus Braunau/Simbach
City
Braunau
ZIP/Postal Code
5280
Country
Austria
Facility Name
Landeskrankenhaus Bruck/Mur
City
Bruck/Mur
ZIP/Postal Code
8600
Country
Austria
Facility Name
Landeskrankenhaus Graz West
City
Graz
ZIP/Postal Code
8020
Country
Austria
Facility Name
Univ. Klinik für Innere Medizin III Innsbruck
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Facility Name
Univ. Klinik für Innere Medizin II
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Charite- University Medicine Campus Benjamin Franklin
City
Berlin
ZIP/Postal Code
D-12200
Country
Germany
Facility Name
Klinikum Villingen Kardiologie
City
Darmstadt
ZIP/Postal Code
64283
Country
Germany
Facility Name
Facharzt fur Innere Medizin/Kardiologie
City
Ludwigshafen
ZIP/Postal Code
D-67063
Country
Germany
Facility Name
Universitätsmedizin Mannheim - I. Medizinische Klinik
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
Klinikum der Universität Regensburg
City
Regensburg
ZIP/Postal Code
93053
Country
Germany
Facility Name
Universtitätsklinikuim Ulm
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Facility Name
Ziekenhuis Rijnstate
City
Arnhem
State/Province
NL
ZIP/Postal Code
6815 AD
Country
Netherlands
Facility Name
Catharina Hospital Eindhoven
City
Eindhoven
ZIP/Postal Code
5623 EJ
Country
Netherlands
Facility Name
Isala Klinieken, Locatie de Weezenlanden
City
Zwolle
ZIP/Postal Code
8011 JW
Country
Netherlands
Facility Name
Polsko - Amerykańskie Kliniki Serca II Oddział Kardiologiczny American Heart of Poland Sp. z o.o.
City
Bielsko-Biała
ZIP/Postal Code
43316
Country
Poland
Facility Name
Krakowskie Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii
City
Krakow
ZIP/Postal Code
30693
Country
Poland
Facility Name
Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie, Centrum Interwencyjne Leczenia Chorób Serca i Naczyń
City
Kraków
ZIP/Postal Code
31102
Country
Poland
Facility Name
SPZOZ Szpital Uniwersytecki w Krakowie, Samodzielna Pracownia Hemodynamiki i Angiografii
City
Kraków
ZIP/Postal Code
31501
Country
Poland
Facility Name
Pracownia Hemodynamiki Oddziału Kardiologicznego Wojewódzkiego Centrum Medycyny w Opolu
City
Opole
ZIP/Postal Code
45418
Country
Poland
Facility Name
Centrum Kardiologii Inwazyjnej GVM Carint
City
Oswiecim
ZIP/Postal Code
32600
Country
Poland
Facility Name
Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie Pracownia Hemodynamiki I Katedry i Kliniki Kardiologii
City
Warszawa
ZIP/Postal Code
2097
Country
Poland
Facility Name
Instytut Kardiologii im. Prymasa Tysiąclecia Kardynała Stefana Wyszyńskiego,I Samodzielna Pracownia Hemodynamiki
City
Warszawa
ZIP/Postal Code
4628
Country
Poland
Facility Name
University Hospitals of Leicester - Glenfield Hospital
City
Leicester
State/Province
U.k.
ZIP/Postal Code
LE3 9QP
Country
United Kingdom
Facility Name
King's College Hospital
City
London
State/Province
U.k.
ZIP/Postal Code
SE5 9RS
Country
United Kingdom
Facility Name
Manchester Royal Infirmary
City
Manchester
State/Province
U.k.
ZIP/Postal Code
M13 9WL
Country
United Kingdom
Facility Name
Wythenshawe Hospital
City
Manchester
State/Province
U.k.
ZIP/Postal Code
M23 9LT
Country
United Kingdom
Facility Name
Southampton University Hospital
City
Southampton
State/Province
U.k.
ZIP/Postal Code
SO16 6UD
Country
United Kingdom
Facility Name
Royal Victoria Hospital, Belfast Trust
City
Belfast
ZIP/Postal Code
BT12 6BA
Country
United Kingdom
Facility Name
Bristol Heart Institute
City
Bristol
ZIP/Postal Code
BS2 8HW
Country
United Kingdom
Facility Name
Golden Jubilee National Hospital
City
Glasgow
ZIP/Postal Code
G81 4DY
Country
United Kingdom
Facility Name
Freeman Hospital
City
Newcastle-upon-Tyne
ZIP/Postal Code
NE7 7DN
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
28828881
Citation
Giustino G, Redfors B, Brener SJ, Kirtane AJ, Genereux P, Maehara A, Dudek D, Neunteufl T, Metzger DC, Crowley A, Mehran R, Gibson CM, Stone GW. Correlates and prognostic impact of new-onset heart failure after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the INFUSE-AMI trial. Eur Heart J Acute Cardiovasc Care. 2018 Jun;7(4):339-347. doi: 10.1177/2048872617719649. Epub 2017 Aug 22.
Results Reference
derived
PubMed Identifier
25497252
Citation
Tomey MI, Mehran R, Brener SJ, Maehara A, Witzenbichler B, Dizon JM, El-Omar M, Xu K, Gibson CM, Stone GW. Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: an analysis of intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI). Am Heart J. 2015 Jan;169(1):86-93. doi: 10.1016/j.ahj.2014.06.019. Epub 2014 Jul 3.
Results Reference
derived
PubMed Identifier
25060015
Citation
Guerchicoff A, Brener SJ, Maehara A, Witzenbichler B, Fahy M, Xu K, Gersh BJ, Mehran R, Gibson CM, Stone GW. Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). JACC Cardiovasc Interv. 2014 Jul;7(7):733-40. doi: 10.1016/j.jcin.2014.01.166.
Results Reference
derived
PubMed Identifier
24084626
Citation
Stone GW, Witzenbichler B, Godlewski J, Dambrink JH, Ochala A, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Dizon JM, Wolff SD, Brener SJ, Mehran R, Maehara A, Gibson CM. Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: one-year results from the INFUSE-AMI trial. Circ Cardiovasc Interv. 2013 Oct 1;6(5):527-34. doi: 10.1161/CIRCINTERVENTIONS.113.000644. Epub 2013 Oct 1.
Results Reference
derived
PubMed Identifier
23866184
Citation
Brener SJ, Maehara A, Dizon JM, Fahy M, Witzenbichler B, Parise H, El-Omar M, Dambrink JH, Mehran R, Oldroyd K, Gibson CM, Stone GW. Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial. JACC Cardiovasc Interv. 2013 Jul;6(7):718-24. doi: 10.1016/j.jcin.2013.03.013.
Results Reference
derived
PubMed Identifier
23816023
Citation
Brener SJ, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar M, Dambrink JH, Genereux P, Mehran R, Oldroyd K, Parise H, Gibson CM, Stone GW. Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. Am Heart J. 2013 Jul;166(1):64-70. doi: 10.1016/j.ahj.2013.03.029. Epub 2013 Apr 30.
Results Reference
derived
PubMed Identifier
22447888
Citation
Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM; INFUSE-AMI Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012 May 2;307(17):1817-26. doi: 10.1001/jama.2012.421. Epub 2012 Mar 25.
Results Reference
derived
PubMed Identifier
21392601
Citation
Gibson CM, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW. Rationale and design of the INFUSE-AMI study: A 2 x 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. Am Heart J. 2011 Mar;161(3):478-486.e7. doi: 10.1016/j.ahj.2010.10.006. Epub 2011 Jan 28.
Results Reference
derived

Learn more about this trial

The INFUSE - Anterior Myocardial Infarction (AMI) Study

We'll reach out to this number within 24 hrs